Welcome to the bioMérieux Clinical Diagnostics website
 

Products

VIDAS® Lyme IgM and VIDAS® Lyme IgG



VIDAS® Lyme IgM and VIDAS® Lyme IgG
Clear-cut immune status and rapid, differential diagnosis

These 2 new generation tests will help you provide patients with differential diagnosis of Lyme borreliosis (caused by all the main Borrelia strains – sensu stricto, afzelii, garinii) in just 27 minutes. Both tests are for use on VIDAS® an automated immunoanalyzer that is greatly appreciated worldwide for its simplicity, flexibility and accuracy.



VIDAS Lyme IgM and VIDAS Lyme IgG advantages:

Clear-cut serological profile
Since IgG and IgM results are separate Lyme borreliosis can be classed as early or late/chronic, active or immune. This differential diagnosis ensures patients receive rapid, optimized treatment depending on their stage of infection.

High specificity and sensitivity
To ensure you have less rework and confirmatory tests and only patients with Lyme borreliosis are treated then having tests with both high specificity and sensitivity is essential*.
It also means there is low contamination reactivity with syphilis and other infectious diseases*.
To increase specificity which is important to have a truely differential diagnosis both tests use innovative recombinant chimeric proteins* (VlsE, DbpA, OspC).
 

SENSITIVITY (serum results from 2 evaluation sites)

Pathology
VIDAS Lyme IgM
VIDAS Lyme IgG VIDAS Lyme IgM + IgG combined
Erythema migrans


53.9%
[43.8 - 63.7%]
N=104

 


54.8%
[44.7 - 64.6%]
N=104

 

79.8%
[70.8 – 87.0%]
N=104

 
Neuroborreliosis
46.2%

[37.4 - 55.1%]
N=130

 

90.8%
[84.4 - 95.1%]
N=130

 

91.5%
[85.4 - 95.7%]
N=130

 
Arthritis/
acrodermatitis

38.3%
[27.7 - 49.7%]
N=81

 

97.5%
[91.4 - 99.7%]
N=81

 

97.5%
[91.4 - 99.7%]
N=81
**
 

  ** 17 samples were tested with VIDAS Lyme IgG only and were not taken into account in the VIDAS Lyme IgM sensitivity analysis

SPECIFICITY (serum results from 2 evaluation sites)

Low prevalence area
N=273
High prevalence area
N=302

VIDAS Lyme IgM

 
VIDAS Lyme IgG VIDAS Lyme IgM VIDAS Lyme IgG
96.3%
[93.4 - 98.2%]
99.3%
[97.4 - 99.9%]
97.7%
[95.3 - 99.1%]
99.7%
[98.2 - 99.9%]


Easy result interpretation
To avoid unnecessary patient anxiety and additional testing there is no equivocal zone for VIDAS Lyme IgG results.

Diagnostic aid for Neuroborreliosis
In the case of neurological symptoms of Lyme borreliosis the specific detection of Borrelia burgdorferi IgG antibodies in CSF samples helps support the diagnosis of Neuroborreliosis*.

Cost effective, streamlined workflow
VIDAS automation is known for its:

  • Ease-of-use
  • Rapid results – 27 minutes for these 2 tests
  • Protocol compatibility between VIDAS  Lyme IgM and VIDAS Lyme IgG (same compartment can be used)
  • Single-dose test
  • Calibration only once every 28 days

This puts you in control of your workflow at all times and ensures you can offer a maximum of information rapidly.


Download scientific posters :
ECCMID Congress 2010
ICLB Congress 2010



VIDAS Lyme IgM ref. 30319
VIDAS Lyme IgG ref. 30320


Download technical specifications


* see package insert for more details



Please consult our local company or representatives for the availability of these products in your country.
For more information
Click here to contact us
Complete Product List
VIDAS® Lyme IgM and VIDAS® Lyme IgG
VIDAS® Lyme IgM and VIDAS® Lyme IgG